Introduction
Ovarian tumors are a rare cause of precocious pseudopuberty, accounting for around 1% of all cases. Least uncommon is the rare granulosa-theca cell tumor and presentation is rare before 4 years 1 .
Case report
A previously healthy 9-month-old girl with a normal birth history and development presented with a history of significant per vaginal bleeding for 4 days duration ( Figure 1 ).
Figure 1 Per vaginal bleeding
Her anthropometric measurements were as follows. Oestradiol levels were greatly elevated at 608.0 pg/ml (less than 40 in prepubertal girls) with normal levels of human chorionic gonadotrophin (HCG) and alpha fetoprotein (AFP) levels. Gonadotrophin levels were unmeasurable with the available assays. Her bone age was slightly advanced to 18 months.
At surgery a well encapsulated tumour arising from right ovary of 7 x 6cm was removed (stage Ia ) There were no tumor deposits in the peritoneal cavity ( Figure 2 ).
Figure 2 Well encapsulated tumour
Microscopic appearance was that of a juvenile granulosa cell tumor with cells containing rounded moderately hyperchromatic nuclei and abundant eosinophilic cytoplasm.
Discussion
At presentation this girl had bleeding per vagina for 4 days duration in the absence of breast development and genital hair growth. The differential diagnoses considered were isosexual precocious pseudopuberty, foreign body and genital rhabdomyosarcoma.
However, clinical finding of a pelvic lump made the latter two possibilities unlikely.
Following surgical treatment bleeding quickly improved and she was referred to the oncologist for a decision regarding further treatment.
Granulosa-theca cell tumors, more commonly known as granulosa cell tumors (GCTs), belong to sex cordstromal group origin. GCTs account for approximately 2% of all ovarian tumors and can be divided in to adult (95%) and juvenile (5%) types 2 . GCTs are thought to be tumors of low malignant potential, most following a benign course with only a small percentage showing aggressive behaviour 3 . More than 90% are diagnosed before spread occurs outside ovary. Five-year survival rates usually are 90-95% for stage I tumors.
